Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × brodalumab × 90 days × Clear all
NCT06673329 2026-05-13

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms